Evolus (EOLS) News Today → Warren Buffett's 'mystery stock' (From Stansberry Research) (Ad) Free EOLS Stock Alerts $13.40 -0.19 (-1.40%) (As of 10:56 AM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 20 at 8:30 AM | businesswire.comEvolus Announces Positive Data from Pivotal Trial for First Two Evolysse™ Dermal Filler Products at 2024 SCALE MeetingMay 16, 2024 | insidertrades.comDavid N. Gill Sells 3,643 Shares of Evolus, Inc. (NASDAQ:EOLS) StockMay 16, 2024 | finance.yahoo.comDirector Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS)May 16, 2024 | finance.yahoo.comDirector David Gill Sells 10,361 Shares of Evolus Inc (EOLS)May 16, 2024 | americanbankingnews.comDavid Moatazedi Sells 16,051 Shares of Evolus, Inc. (NASDAQ:EOLS) StockMay 15, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) CFO Sandra Beaver Sells 2,423 SharesMay 15, 2024 | finance.yahoo.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women’s Wear Daily Beauty CEO SummitMay 15, 2024 | businesswire.comEvolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau® at the Women's Wear Daily Beauty CEO SummitMay 14, 2024 | marketbeat.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 2,423 Shares of StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 2,423 shares of the firm's stock in a transaction dated Friday, May 10th. The stock was sold at an average price of $12.72, for a total transaction of $30,820.56. Following the transaction, the chief financial officer now owns 151,778 shares of the company's stock, valued at approximately $1,930,616.16. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.May 13, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Evolus (EOLS)May 12, 2024 | americanbankingnews.comEvolus' (EOLS) Buy Rating Reiterated at Needham & Company LLCMay 10, 2024 | finance.yahoo.comEvolus’ Sandra Beaver Named Orange County Business Journal’s Public Company CFO of the YearMay 10, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 10, 2024 | businesswire.comEvolus' Sandra Beaver Named Orange County Business Journal's Public Company CFO of the YearMay 10, 2024 | markets.businessinsider.comEvolus’s Strong Q1 Performance and Solid Growth Trajectory Justify Buy RatingMay 10, 2024 | markets.businessinsider.comEvolus Outperforms Expectations with Strong Q1 Sales and Promising Growth TrajectoryMay 10, 2024 | americanbankingnews.comHC Wainwright Reiterates Buy Rating for Evolus (NASDAQ:EOLS)May 9, 2024 | finance.yahoo.comEvolus First Quarter 2024 Earnings: Revenues Beat Expectations, EPS LagsMay 8, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call TranscriptMay 8, 2024 | marketbeat.comEvolus (NASDAQ:EOLS) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and issued a $27.00 target price on shares of Evolus in a research report on Wednesday.May 8, 2024 | finance.yahoo.comEvolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ...May 7, 2024 | investorplace.comEOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024May 7, 2024 | finance.yahoo.comEvolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant GrowthMay 7, 2024 | businesswire.comEvolus Reports First Quarter 2024 Results and Provides Business UpdateMay 3, 2024 | finance.yahoo.comThe 15% return this week takes Evolus' (NASDAQ:EOLS) shareholders one-year gains to 59%April 30, 2024 | marketbeat.comEvolus (EOLS) Scheduled to Post Earnings on TuesdayEvolus (NASDAQ:EOLS) will be releasing earnings after the market closes on Tuesday, May 7, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=588133)April 23, 2024 | businesswire.comEvolus to Report First Quarter Financial Results on May 7, 2024April 18, 2024 | investing.comEvolus reports 6-month efficacy of Jeuveau in glabellar lines studyApril 17, 2024 | finance.yahoo.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for "Extra-Strength" 40U Formulation of Jeuveau®April 17, 2024 | businesswire.comEvolus Announces Publication of Safety and Duration Data from Phase 2 Study for “Extra-Strength” 40U Formulation of Jeuveau®April 16, 2024 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Sees Significant Decrease in Short InterestEvolus, Inc. (NASDAQ:EOLS - Get Free Report) was the target of a significant drop in short interest during the month of March. As of March 31st, there was short interest totalling 4,650,000 shares, a drop of 6.6% from the March 15th total of 4,980,000 shares. Based on an average trading volume of 657,700 shares, the short-interest ratio is currently 7.1 days. Approximately 9.8% of the company's shares are sold short.April 13, 2024 | marketbeat.comVanguard Group Inc. Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Vanguard Group Inc. grew its holdings in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 37.9% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,698,647 shares of the company's stock after buying an additApril 12, 2024 | businesswire.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 10, 2024 | marketbeat.comNeedham & Company LLC Reaffirms "Buy" Rating for Evolus (NASDAQ:EOLS)Needham & Company LLC reissued a "buy" rating and issued a $22.00 price target on shares of Evolus in a report on Wednesday.April 9, 2024 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) is Stonepine Capital Management LLC's Largest PositionStonepine Capital Management LLC lifted its stake in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 3.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,333,004 shares of the company's stock after purchasingApril 6, 2024 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) is favoured by institutional owners who hold 57% of the companyApril 3, 2024 | marketbeat.comEvolus (NASDAQ:EOLS) Shares Gap Down to $13.76Evolus (NASDAQ:EOLS) Shares Gap Down to $13.76March 30, 2024 | insidertrades.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 6,236 Shares of StockMarch 29, 2024 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Insider David Moatazedi Sells 6,236 SharesEvolus, Inc. (NASDAQ:EOLS - Get Free Report) insider David Moatazedi sold 6,236 shares of the company's stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $13.86, for a total transaction of $86,430.96. Following the transaction, the insider now owns 689,614 shares in the company, valued at approximately $9,558,050.04. The sale was disclosed in a filing with the SEC, which is available at this link.March 26, 2024 | finance.yahoo.comEvolus to Participate in the 23rd Annual Needham Virtual Healthcare ConferenceMarch 24, 2024 | insidertrades.comEvolus, Inc. (NASDAQ:EOLS) CFO Sells $78,954.24 in StockMarch 21, 2024 | marketbeat.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) CFO Sells 5,672 Shares of StockEvolus, Inc. (NASDAQ:EOLS - Get Free Report) CFO Sandra Beaver sold 5,672 shares of the firm's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $13.92, for a total transaction of $78,954.24. Following the sale, the chief financial officer now owns 154,201 shares in the company, valued at approximately $2,146,477.92. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.March 21, 2024 | msn.comEvolus (NASDAQ:EOLS): An Attractive Aesthetics Stock for Growth InvestorsMarch 20, 2024 | seekingalpha.comEvolus: Smooth Progress As Management Targets $700m Aesthetics Franchise Revenues By 2028March 17, 2024 | marketbeat.comWalleye Capital LLC Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)Walleye Capital LLC raised its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 650.1% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 293,084 shares of the company's stock after acquiring an additional 254,013 shaMarch 14, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Sangamo Biosciences (SGMO) and Evolus (EOLS)March 12, 2024 | wsj.comEvolus Inc.March 12, 2024 | benzinga.comLatest News for Evolus Stock (NASDAQ:EOLS)March 11, 2024 | markets.businessinsider.comEvolus Poised for Growth: Buy Rating Affirmed with $25 Price Target Amid Profitability Forecast and Competitive Market PositioningMarch 11, 2024 | markets.businessinsider.comEvolus Reports Pricing Of $50 Mln Underwritten Offering Of Common Stock Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address This Apple-like Innovator is Revolutionizing Healthcare (Ad)AI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world. Click here to learn more about the booming eHealth industry EOLS Media Mentions By Week EOLS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EOLS News Sentiment▼0.470.42▲Average Medical News Sentiment EOLS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EOLS Articles This Week▼123▲EOLS Articles Average Week Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Arcturus Therapeutics News Today Longboard Pharmaceuticals News Today ALX Oncology News Today Tango Therapeutics News Today Disc Medicine News Today Praxis Precision Medicines News Today Dianthus Therapeutics News Today Zentalis Pharmaceuticals News Today Pliant Therapeutics News Today PureTech Health News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EOLS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority Gold4 Cryptos BETTER than BitcoinTrue Market InsidersDoes this make you sick?Allegiance GoldBill Gates is all about this tiny $2 stockTimothy SykesUrgent Nvidia WarningAltimetryThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaThis Apple-like Innovator is Revolutionizing HealthcareWall Street StarShocking: One AI startup's revenue could surge 4,735%Manward Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.